CNP and chronic myelogenous leukemia, BCR-ABL1 positive: In this respect, in the recent in vitro study of Asif et al. (2023), CML-CNP showed a dose-dependent increase in percentage protection of human RBC membrane stabilization and anti-inflammatory activity.